Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Inclusion Criteria: Patients with newly diagnosed, symptomatic multiple myeloma based on the following criteria: * Presence of an M-component in serum and/or urine plus clonal plasma cells in the bone marrow and/or a documented clonal plasmacytoma PLUS one or more of the following: * Calcium elevation (11.5 mg/dl) \[42.65 mmol/l\] * Renal insufficiency (1.5 x the ULN of serum creatinine) * Anemia (hemoglobin \<=10 g/dl or 2 g/dl \<= normal) * Bone disease (lytic lesions or osteopenia) Measurable disease is defined at least one of the following three measurements: * Serum M-protein \>=1 g/dl ( or 10 g/l) * Urine M-protein \>=200 mg/24 h * Serum FLC assay: Involved FLC level \>=10 mg/dl (\>=100 mg/l) provided serum FLC ratio is abnormal * Measurable plasmacytoma * NOTE: If a patient meets the criteria for symptomatic multiple myeloma but does not meet serum M-protein, urine M-protein or serum FLC levels stated above, percent plasma cells in bone marrow will be used to follow response. Laboratory test results within these ranges: * Absolute neutrophil count \>= 1.0 x 109/L * Platelet count \>= 50 x 10(9)/L * Hemoglobin \>= 9 gm/dl * Serum creatinine \<= 2.5mg/dL. * Total bilirubin \<=1.5 x upper limit of normal * AST (SGOT) and ALT (SGPT) \<= 3 x ULN Exclusion Criteria: * Known hypersensitivity to thalidomide * The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. * Patients with a solitary plasmacytoma * Patients with uncontrolled diabetes * Patients with ≥ Grade 3 sensory neuropathy * History of cardiac disease, with NYHA Class II or greater